Silk Road Medical (FRA:2OW) 3-Year Revenue Growth Rate : 26.00% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical 3-Year Revenue Growth Rate?

Silk Road Medical's Revenue per Share for the three months ended in Mar. 2024 was €1.14.

During the past 12 months, Silk Road Medical's average Revenue per Share Growth Rate was 15.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 26.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Silk Road Medical was 56.70% per year. The lowest was 12.00% per year. And the median was 30.25% per year.

Competitive Comparison of Silk Road Medical's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Silk Road Medical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silk Road Medical's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's 3-Year Revenue Growth Rate falls into.

Silk Road Medical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Silk Road Medical (FRA:2OW) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Silk Road Medical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical (FRA:2OW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

SILK:USA

Address

1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089

Website

https://www.silkroadmed.com

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical (FRA:2OW) Headlines

No Headlines